Components of The Stork® OTC

The Conceptacle®

The Conceptacle consists of a silicone, condom-like sheath with an HSSA tested silicone cervical cap resting within the reservoir. The Conceptacle is used to collect the semen during intercourse but can alternatively be used with donor sperm. The semen (or donor sperm) collected remains in the cervical cap in its reservoir. The cervical cap is removed from the sheath and placed into the applicator for tracking into the vaginal tract.

The Applicator

The Applicator cradles and compresses the cervical cap for ease of tracking through the vagina to the opening of the cervical os. There are three activation buttons on the applicator that the patient will engage to use the product.

The cervical cap is cradled and compressed with the Plunger Tab (Button 1)*. Once the device is placed into the vaginal tract by the user, the semen (or donor sperm) is pushed from the reservoir tip towards the mouth of the cap with the Plunger Release Button (Button 2)**. The cap is released from the device using the Cap Release Button (Button 3)***. The cervical cap remains at the cervix for 4-6 hours after which it is then removed by using the tampon-like pull cord.



Applicator Buttons

Button 1* - Plunger Tab (seals the cervical cap)

Button 2** - Plunger Release (opens the cervical cap)

Button 3*** - Cap Release (releases the cervical cap, attaching a tampon-like pull cord)

The Stork® OTC Conception Device.

- FDA-cleared device for home use
- Assists conception at home
- Cost-effective: a lower-cost option prior to investing in in-clinic treatments
- Easy to use: 3 simple steps
- Approved for use in Canada and the UK (CE0459)

Become a Provider

For wholesale pricing or to have a representative come to your office contact us by email at info@storkotc.com or by phone at (412) 200-7996.

Your patients can purchase The Stork OTC over the counter online and in select stores with the following retailers:



Walgreens



About Rinovum® Women's Health

Rinovum Women's Health is a privately held women's health company dedicated to bringing products into the market that will enhance women's lives and empower them to take charge of their health. Our OTC product, The Stork® OTC, is a device for reproductive health to aid in natural conception in the privacy of home. We aim to provide products that are easy-to-use, safe, and offer an additional option before more expensive treatments are considered.

If you are a healthcare professional and have any questions relating to The Stork OTC, please contact Rinovum by email at info@rinovum.com or by telephone at +1 (412) 200-7996.

The Stork Ib2C, Inc.,
A Rinovum Women's Health Company
300 Oxford Drive, Suite 330
Monroeville, PA 15146
www.rinovum.com

Refer to the Instructions for Use with this product for complete instructions, warnings, and precautions prior to usir this product.

🗅 2017 The Stork Ib2C, Inc., A Rinovum Women's Health Company. ART 0476 R0



Disclaimer: This device is intended as an aid in conception and does not guarantee pregnancy.

The Stork® OTC Conception Device.

The Stork OTC is designed to be a "next step" treatment option that goes beyond ovulation tracking for those that are trying to conceive. The FDA-cleared product helps couples who are trying to conceive in the privacy and comfort of home. The Stork OTC gives couples the ability to use cervical cap insemination as an aid in conception. The device is intended to assist those with common difficulties such as: diminished sperm count, sperm motility issues, unfavorable vaginal environment and unexplained infertility. The Stork OTC allows couples to take a proactive approach in addressing these issues.

+ Improving Options For Infertility

Couples today are seeking out less invasive, more affordable options to complement their path to becoming pregnant. Many couples are using diagnostic tools to enhance their chances for conception. The Stork OTC can provide an additional option designed to complement the fertility treatment path, whether couples are just thinking about starting their family or have been trying for longer. Priced lower than alternative treatments options, The Stork OTC provides an economical, "next step" treatment option for couples to try that goes beyond ovulation tracking before advancing into more costly, in-clinic treatments.

+ Technology Improvement

The device utilizes cervical cap insemination, a technique healthcare professionals have used as an effective, in-clinic treatment option for decades. Historical cervical cap insemination success rates have been well documented with success rates between 10-20%. The Stork OTC allows couples to use this treatment method while in the privacy of home. The Stork OTC improves on the technique, combining a condom-like integrated collection/delivery with a tampon-like anatomical delivery system that is atraumatic to ejaculate and the vaginal environment. From collection to placement, the process is completed by engaging ONLY three buttons. The system collects, delivers, and places the semen close to the cervical os.

The product can be used as a complement to intercourse during the traditional six to twelve month waiting period or longer, before couples are referred out for more costly, in-clinic treatments. The Stork OTC is recommended for use just during ovulation. Patients are encouraged to use the device with an ovulation test to determine their most fertile days.

1) Obstet. Gynecol.: 1982 Aug: 60(2): 195-9

Get a higher concentration of sperm closer to the cervix.

Our post coital study demonstrates on average a 3.23 higher value of sperm concentration at the cervix compared to the value of sperm concentration with natural intercourse, for 85% of study participants.





The Stork® OTC



The Stork® OTC delivers a 3 times higher concentration of sperm score value to the cervix compared to the concentration of sperm at cervix with natural intercourse.*

Journal References



Dr. Michael J. Pelekanos. Vice Chairman, Department of Obstetrics and Gynecology, Forbes Regional Hospital in Monroeville, PA.



Study was performed over a (November 2014-August 2015).



This Postcoital Sperm Assessment published in the Surgical Technology International, Issue XXII. December 2015.



Harry Reich, MD, FACOG, FRCOG.